用于心力衰竭的HeartMate 3与保存的射出小部分:在体外血液动力学评估和解剖学适配
Nina Langer1,2,3, Andrew F Stephens4,5, Michael Šeman4,6,7
1Cardio-Respiratory Engineering and Technology Laboratory (CREATElab), Department of Mechanical and Aerospace Engineering, Monash University, Melbourne, VIC, Australia. nina.langer@monash.edu.
Annals of biomedical engineering
|July 16, 2024
概括
这项研究使用HeartMate3心室辅助装置 (VAD) 在心脏衰竭的左心房到大动脉配置中进行了探索,其中保留了喷射分数 (HFpEF). 结果显示,在精选的HFpEF患者中,有潜力降低左心房压力,解决解剖学挑战.
科学领域:
- 心血管医学 心血管医学
- 生物医学工程 生物医学工程
- 医疗器械 医疗器械
背景情况:
- 保存喷射分数 (HFpEF) 的心力衰竭约占心力衰竭病例的50%,并呈现出不同的表型.
- 许多HFpEF患者的左心室腔体较小,使使用心室辅助装置 (VAD) 变得复杂.
- 左心房至大动脉 (LA-Ao) VAD配置可以缓解左心房平均压力 (MLAP) 的升高,并改善生活质量.
研究的目的:
- 在模拟的HFpEF患者中评估VAD的解剖学兼容性和左心房卸载能力.
- 评估在LA-Ao配置中的HeartMate3 VAD在降低HFpEF中MLAP方面的有效性.
主要方法:
- 一个心血管模拟器模拟了HFpEF的LA-Ao配置中的HeartMate3 VAD.
- 血液动力学参数被记录在休息和运动期间的七个流率.
- 来自HFpEF和心力衰竭的CT扫描与减少喷射分数的患者被用于解剖比较和虚拟适应性评估.
主要成果:
- 1L/min的HeartMate3流量可以将MLAP从静止时的15mmHg降低到11mmHg.
- 在运动模拟期间,需要6L/分钟的HM3支持来使MLAP从29mmHg降低到16mmHg.
- 在6名HFpEF患者身上,HM3装置在解剖学上适合;其余的患者经历了冲击 (4-14毫米).
结论:
- 在LA-Ao配置中的HeartMate3 VAD显示出它有望在特定的HFpEF患者中卸载左心房并减轻肺堵塞.
- 在手术前进行解剖适合分析对于解决与尺寸相关的限制和确保在HFpEF中适合LA-Ao VAD植入的适合性至关重要.
相关概念视频
01:30Heart Failure IV: Classification and Diagnostic Evaluation
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...